nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—PTGS2—malignant glioma	0.352	1	CbGaD
Celecoxib—Wound infection—Temozolomide—malignant glioma	0.00907	0.0447	CcSEcCtD
Celecoxib—ORM1—vertebral column—malignant glioma	0.00799	0.0746	CbGeAlD
Celecoxib—PDPK1—embryo—malignant glioma	0.00607	0.0567	CbGeAlD
Celecoxib—MAPK14—blood vessel—malignant glioma	0.00545	0.0509	CbGeAlD
Celecoxib—PDPK1—retina—malignant glioma	0.00537	0.0502	CbGeAlD
Celecoxib—Cerebral infarction—Carmustine—malignant glioma	0.00473	0.0233	CcSEcCtD
Celecoxib—Clotting—Temozolomide—malignant glioma	0.00417	0.0206	CcSEcCtD
Celecoxib—PDPK1—medulla oblongata—malignant glioma	0.00388	0.0362	CbGeAlD
Celecoxib—Haemorrhage intracranial—Temozolomide—malignant glioma	0.00363	0.0179	CcSEcCtD
Celecoxib—PDPK1—midbrain—malignant glioma	0.00355	0.0331	CbGeAlD
Celecoxib—PDPK1—spinal cord—malignant glioma	0.00346	0.0323	CbGeAlD
Celecoxib—MAPK14—embryo—malignant glioma	0.00325	0.0303	CbGeAlD
Celecoxib—MAPK14—brainstem—malignant glioma	0.00298	0.0278	CbGeAlD
Celecoxib—Transient ischaemic attack—Temozolomide—malignant glioma	0.00295	0.0145	CcSEcCtD
Celecoxib—PDPK1—central nervous system—malignant glioma	0.00281	0.0262	CbGeAlD
Celecoxib—Cerebral haemorrhage—Carmustine—malignant glioma	0.00278	0.0137	CcSEcCtD
Celecoxib—PDPK1—cerebellum—malignant glioma	0.00274	0.0256	CbGeAlD
Celecoxib—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00269	0.0133	CcSEcCtD
Celecoxib—Sulfaphenazole—CYP2B6—malignant glioma	0.00268	0.605	CrCbGaD
Celecoxib—MAPK14—telencephalon—malignant glioma	0.00264	0.0247	CbGeAlD
Celecoxib—CA14—telencephalon—malignant glioma	0.00257	0.024	CbGeAlD
Celecoxib—Transaminases increased—Carmustine—malignant glioma	0.00253	0.0125	CcSEcCtD
Celecoxib—Haemorrhoids—Temozolomide—malignant glioma	0.00253	0.0125	CcSEcCtD
Celecoxib—Deep vein thrombosis—Temozolomide—malignant glioma	0.00245	0.0121	CcSEcCtD
Celecoxib—Tooth disorder—Temozolomide—malignant glioma	0.00229	0.0113	CcSEcCtD
Celecoxib—PDPK1—brain—malignant glioma	0.00223	0.0208	CbGeAlD
Celecoxib—Influenza-like symptoms—Temozolomide—malignant glioma	0.00208	0.0103	CcSEcCtD
Celecoxib—CA14—medulla oblongata—malignant glioma	0.00202	0.0189	CbGeAlD
Celecoxib—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00201	0.00992	CcSEcCtD
Celecoxib—CA12—telencephalon—malignant glioma	0.002	0.0187	CbGeAlD
Celecoxib—Herpes zoster—Temozolomide—malignant glioma	0.00198	0.00975	CcSEcCtD
Celecoxib—Cholestasis—Temozolomide—malignant glioma	0.00196	0.00967	CcSEcCtD
Celecoxib—Otitis media—Temozolomide—malignant glioma	0.00191	0.00943	CcSEcCtD
Celecoxib—Coagulopathy—Temozolomide—malignant glioma	0.00191	0.00943	CcSEcCtD
Celecoxib—MAPK14—spinal cord—malignant glioma	0.00185	0.0173	CbGeAlD
Celecoxib—CA14—midbrain—malignant glioma	0.00185	0.0172	CbGeAlD
Celecoxib—CA14—spinal cord—malignant glioma	0.0018	0.0168	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—malignant glioma	0.00175	0.395	CrCbGaD
Celecoxib—Breast pain—Temozolomide—malignant glioma	0.00171	0.00842	CcSEcCtD
Celecoxib—PTGS2—endothelium—malignant glioma	0.0017	0.0159	CbGeAlD
Celecoxib—Drug interaction—Carmustine—malignant glioma	0.00166	0.00819	CcSEcCtD
Celecoxib—Viral infection—Temozolomide—malignant glioma	0.00165	0.00813	CcSEcCtD
Celecoxib—Herpes simplex—Temozolomide—malignant glioma	0.00161	0.00797	CcSEcCtD
Celecoxib—PTGS2—blood vessel—malignant glioma	0.00157	0.0146	CbGeAlD
Celecoxib—Hearing impaired—Temozolomide—malignant glioma	0.00156	0.00771	CcSEcCtD
Celecoxib—Pulmonary embolism—Carmustine—malignant glioma	0.00154	0.0076	CcSEcCtD
Celecoxib—Injection site reaction—Carmustine—malignant glioma	0.00153	0.00755	CcSEcCtD
Celecoxib—CA9—cerebellum—malignant glioma	0.00151	0.0141	CbGeAlD
Celecoxib—MAPK14—central nervous system—malignant glioma	0.0015	0.014	CbGeAlD
Celecoxib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00149	0.00734	CcSEcCtD
Celecoxib—Pulmonary embolism—Temozolomide—malignant glioma	0.00149	0.00734	CcSEcCtD
Celecoxib—Vaginal inflammation—Temozolomide—malignant glioma	0.00149	0.00734	CcSEcCtD
Celecoxib—Urinary incontinence—Carmustine—malignant glioma	0.00149	0.00734	CcSEcCtD
Celecoxib—Skin exfoliation—Carmustine—malignant glioma	0.00147	0.00725	CcSEcCtD
Celecoxib—Candida infection—Carmustine—malignant glioma	0.00147	0.00725	CcSEcCtD
Celecoxib—MAPK14—cerebellum—malignant glioma	0.00147	0.0137	CbGeAlD
Celecoxib—Neuropathy—Carmustine—malignant glioma	0.00145	0.00713	CcSEcCtD
Celecoxib—Influenza like illness—Temozolomide—malignant glioma	0.00145	0.00713	CcSEcCtD
Celecoxib—Urinary incontinence—Temozolomide—malignant glioma	0.00144	0.00709	CcSEcCtD
Celecoxib—CA14—cerebellum—malignant glioma	0.00143	0.0133	CbGeAlD
Celecoxib—Candida infection—Temozolomide—malignant glioma	0.00142	0.00701	CcSEcCtD
Celecoxib—Skin exfoliation—Temozolomide—malignant glioma	0.00142	0.00701	CcSEcCtD
Celecoxib—Vaginal infection—Temozolomide—malignant glioma	0.00141	0.00693	CcSEcCtD
Celecoxib—CA4—brainstem—malignant glioma	0.0014	0.0131	CbGeAlD
Celecoxib—Neuropathy—Temozolomide—malignant glioma	0.0014	0.00689	CcSEcCtD
Celecoxib—Aplastic anaemia—Temozolomide—malignant glioma	0.0014	0.00689	CcSEcCtD
Celecoxib—Neoplasm—Carmustine—malignant glioma	0.00139	0.00687	CcSEcCtD
Celecoxib—Neoplasm—Temozolomide—malignant glioma	0.00135	0.00664	CcSEcCtD
Celecoxib—Sepsis—Carmustine—malignant glioma	0.00134	0.00659	CcSEcCtD
Celecoxib—Thrombophlebitis—Carmustine—malignant glioma	0.00129	0.00637	CcSEcCtD
Celecoxib—Diabetes mellitus—Carmustine—malignant glioma	0.00129	0.00634	CcSEcCtD
Celecoxib—Ear pain—Temozolomide—malignant glioma	0.00127	0.00625	CcSEcCtD
Celecoxib—CA2—embryo—malignant glioma	0.00127	0.0118	CbGeAlD
Celecoxib—Thrombophlebitis—Temozolomide—malignant glioma	0.00125	0.00616	CcSEcCtD
Celecoxib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00124	0.00613	CcSEcCtD
Celecoxib—CA4—telencephalon—malignant glioma	0.00124	0.0116	CbGeAlD
Celecoxib—Eye pain—Carmustine—malignant glioma	0.00124	0.00611	CcSEcCtD
Celecoxib—Gastroenteritis—Temozolomide—malignant glioma	0.00122	0.00601	CcSEcCtD
Celecoxib—Deafness—Temozolomide—malignant glioma	0.00121	0.00596	CcSEcCtD
Celecoxib—Hepatic failure—Temozolomide—malignant glioma	0.0012	0.00593	CcSEcCtD
Celecoxib—Eye pain—Temozolomide—malignant glioma	0.0012	0.0059	CcSEcCtD
Celecoxib—MAPK14—brain—malignant glioma	0.00119	0.0111	CbGeAlD
Celecoxib—CA14—brain—malignant glioma	0.00116	0.0108	CbGeAlD
Celecoxib—CA2—brainstem—malignant glioma	0.00116	0.0108	CbGeAlD
Celecoxib—Hot flush—Temozolomide—malignant glioma	0.00115	0.0057	CcSEcCtD
Celecoxib—Dermatitis exfoliative—Temozolomide—malignant glioma	0.00114	0.00565	CcSEcCtD
Celecoxib—Menopausal symptoms—Temozolomide—malignant glioma	0.00114	0.00565	CcSEcCtD
Celecoxib—CA12—central nervous system—malignant glioma	0.00114	0.0106	CbGeAlD
Celecoxib—Hyponatraemia—Carmustine—malignant glioma	0.00112	0.00554	CcSEcCtD
Celecoxib—CA2—retina—malignant glioma	0.00112	0.0104	CbGeAlD
Celecoxib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00112	0.00552	CcSEcCtD
Celecoxib—ORM1—spinal cord—malignant glioma	0.00111	0.0104	CbGeAlD
Celecoxib—Face oedema—Carmustine—malignant glioma	0.00108	0.00532	CcSEcCtD
Celecoxib—Ataxia—Carmustine—malignant glioma	0.00105	0.00519	CcSEcCtD
Celecoxib—Face oedema—Temozolomide—malignant glioma	0.00104	0.00515	CcSEcCtD
Celecoxib—Liver function test abnormal—Carmustine—malignant glioma	0.00103	0.00509	CcSEcCtD
Celecoxib—CA2—telencephalon—malignant glioma	0.00103	0.00961	CbGeAlD
Celecoxib—CA5B—central nervous system—malignant glioma	0.00102	0.00954	CbGeAlD
Celecoxib—Hypokalaemia—Carmustine—malignant glioma	0.00102	0.00502	CcSEcCtD
Celecoxib—Ataxia—Temozolomide—malignant glioma	0.00102	0.00501	CcSEcCtD
Celecoxib—Dry skin—Temozolomide—malignant glioma	0.00099	0.00489	CcSEcCtD
Celecoxib—Hypokalaemia—Temozolomide—malignant glioma	0.000983	0.00485	CcSEcCtD
Celecoxib—Breast disorder—Temozolomide—malignant glioma	0.000976	0.00482	CcSEcCtD
Celecoxib—CA4—medulla oblongata—malignant glioma	0.000975	0.00911	CbGeAlD
Celecoxib—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000973	0.0048	CcSEcCtD
Celecoxib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000973	0.0048	CcSEcCtD
Celecoxib—Dysphagia—Carmustine—malignant glioma	0.000966	0.00477	CcSEcCtD
Celecoxib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000953	0.0047	CcSEcCtD
Celecoxib—PTGS2—embryo—malignant glioma	0.000934	0.00872	CbGeAlD
Celecoxib—Dysphagia—Temozolomide—malignant glioma	0.000934	0.00461	CcSEcCtD
Celecoxib—Pancytopenia—Carmustine—malignant glioma	0.000918	0.00453	CcSEcCtD
Celecoxib—Sweating increased—Temozolomide—malignant glioma	0.00091	0.00449	CcSEcCtD
Celecoxib—CA12—brain—malignant glioma	0.000904	0.00845	CbGeAlD
Celecoxib—ORM1—central nervous system—malignant glioma	0.000904	0.00844	CbGeAlD
Celecoxib—Bronchitis—Temozolomide—malignant glioma	0.000898	0.00443	CcSEcCtD
Celecoxib—CA4—midbrain—malignant glioma	0.000891	0.00832	CbGeAlD
Celecoxib—Pancytopenia—Temozolomide—malignant glioma	0.000887	0.00437	CcSEcCtD
Celecoxib—Dysuria—Temozolomide—malignant glioma	0.000873	0.00431	CcSEcCtD
Celecoxib—Hyperglycaemia—Carmustine—malignant glioma	0.000872	0.0043	CcSEcCtD
Celecoxib—CA4—spinal cord—malignant glioma	0.00087	0.00812	CbGeAlD
Celecoxib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000868	0.00428	CcSEcCtD
Celecoxib—Pneumonia—Carmustine—malignant glioma	0.000867	0.00427	CcSEcCtD
Celecoxib—Pollakiuria—Temozolomide—malignant glioma	0.000863	0.00426	CcSEcCtD
Celecoxib—Photosensitivity reaction—Temozolomide—malignant glioma	0.000852	0.0042	CcSEcCtD
Celecoxib—Weight increased—Temozolomide—malignant glioma	0.00085	0.00419	CcSEcCtD
Celecoxib—Neuropathy peripheral—Carmustine—malignant glioma	0.000844	0.00417	CcSEcCtD
Celecoxib—Hyperglycaemia—Temozolomide—malignant glioma	0.000842	0.00416	CcSEcCtD
Celecoxib—Stomatitis—Carmustine—malignant glioma	0.00084	0.00414	CcSEcCtD
Celecoxib—Urinary tract infection—Carmustine—malignant glioma	0.000837	0.00413	CcSEcCtD
Celecoxib—Pneumonia—Temozolomide—malignant glioma	0.000837	0.00413	CcSEcCtD
Celecoxib—Infestation—Temozolomide—malignant glioma	0.000833	0.00411	CcSEcCtD
Celecoxib—Infestation NOS—Temozolomide—malignant glioma	0.000833	0.00411	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000825	0.00407	CcSEcCtD
Celecoxib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000816	0.00403	CcSEcCtD
Celecoxib—Stomatitis—Temozolomide—malignant glioma	0.000812	0.004	CcSEcCtD
Celecoxib—CA5B—brain—malignant glioma	0.000811	0.00758	CbGeAlD
Celecoxib—Urinary tract infection—Temozolomide—malignant glioma	0.000809	0.00399	CcSEcCtD
Celecoxib—CA2—medulla oblongata—malignant glioma	0.000809	0.00755	CbGeAlD
Celecoxib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000787	0.00388	CcSEcCtD
Celecoxib—Sinusitis—Temozolomide—malignant glioma	0.000781	0.00385	CcSEcCtD
Celecoxib—Haemoglobin—Carmustine—malignant glioma	0.000777	0.00383	CcSEcCtD
Celecoxib—Haemorrhage—Carmustine—malignant glioma	0.000773	0.00382	CcSEcCtD
Celecoxib—Hypoaesthesia—Carmustine—malignant glioma	0.00077	0.0038	CcSEcCtD
Celecoxib—Hallucination—Carmustine—malignant glioma	0.00077	0.0038	CcSEcCtD
Celecoxib—ABCC4—central nervous system—malignant glioma	0.000767	0.00717	CbGeAlD
Celecoxib—Oedema peripheral—Carmustine—malignant glioma	0.000762	0.00376	CcSEcCtD
Celecoxib—Connective tissue disorder—Carmustine—malignant glioma	0.00076	0.00375	CcSEcCtD
Celecoxib—PTGS2—telencephalon—malignant glioma	0.00076	0.0071	CbGeAlD
Celecoxib—Haemoglobin—Temozolomide—malignant glioma	0.000751	0.00371	CcSEcCtD
Celecoxib—Haemorrhage—Temozolomide—malignant glioma	0.000747	0.00369	CcSEcCtD
Celecoxib—Hepatitis—Temozolomide—malignant glioma	0.000747	0.00369	CcSEcCtD
Celecoxib—Hallucination—Temozolomide—malignant glioma	0.000744	0.00367	CcSEcCtD
Celecoxib—Hypoaesthesia—Temozolomide—malignant glioma	0.000744	0.00367	CcSEcCtD
Celecoxib—Pharyngitis—Temozolomide—malignant glioma	0.000742	0.00366	CcSEcCtD
Celecoxib—CA2—midbrain—malignant glioma	0.000739	0.0069	CbGeAlD
Celecoxib—Urinary tract disorder—Temozolomide—malignant glioma	0.000738	0.00364	CcSEcCtD
Celecoxib—Oedema peripheral—Temozolomide—malignant glioma	0.000736	0.00363	CcSEcCtD
Celecoxib—CYP2D6—brainstem—malignant glioma	0.000736	0.00688	CbGeAlD
Celecoxib—Connective tissue disorder—Temozolomide—malignant glioma	0.000734	0.00362	CcSEcCtD
Celecoxib—Urethral disorder—Temozolomide—malignant glioma	0.000733	0.00361	CcSEcCtD
Celecoxib—Eye disorder—Carmustine—malignant glioma	0.000723	0.00357	CcSEcCtD
Celecoxib—CA2—spinal cord—malignant glioma	0.000721	0.00673	CbGeAlD
Celecoxib—Flushing—Carmustine—malignant glioma	0.000718	0.00354	CcSEcCtD
Celecoxib—Erythema multiforme—Temozolomide—malignant glioma	0.000707	0.00349	CcSEcCtD
Celecoxib—CA4—central nervous system—malignant glioma	0.000705	0.00659	CbGeAlD
Celecoxib—Eye disorder—Temozolomide—malignant glioma	0.000698	0.00345	CcSEcCtD
Celecoxib—Tinnitus—Temozolomide—malignant glioma	0.000697	0.00344	CcSEcCtD
Celecoxib—Cardiac disorder—Temozolomide—malignant glioma	0.000694	0.00342	CcSEcCtD
Celecoxib—Flushing—Temozolomide—malignant glioma	0.000694	0.00342	CcSEcCtD
Celecoxib—Arrhythmia—Carmustine—malignant glioma	0.000691	0.00341	CcSEcCtD
Celecoxib—CA4—cerebellum—malignant glioma	0.000689	0.00644	CbGeAlD
Celecoxib—Alopecia—Carmustine—malignant glioma	0.000683	0.00337	CcSEcCtD
Celecoxib—Angiopathy—Temozolomide—malignant glioma	0.000678	0.00335	CcSEcCtD
Celecoxib—Mental disorder—Carmustine—malignant glioma	0.000678	0.00334	CcSEcCtD
Celecoxib—Immune system disorder—Temozolomide—malignant glioma	0.000675	0.00333	CcSEcCtD
Celecoxib—Mediastinal disorder—Temozolomide—malignant glioma	0.000674	0.00332	CcSEcCtD
Celecoxib—Alopecia—Temozolomide—malignant glioma	0.00066	0.00326	CcSEcCtD
Celecoxib—Mental disorder—Temozolomide—malignant glioma	0.000655	0.00323	CcSEcCtD
Celecoxib—CYP2D6—telencephalon—malignant glioma	0.000653	0.0061	CbGeAlD
Celecoxib—Back pain—Carmustine—malignant glioma	0.000651	0.00321	CcSEcCtD
Celecoxib—Dysgeusia—Temozolomide—malignant glioma	0.000637	0.00314	CcSEcCtD
Celecoxib—Vision blurred—Carmustine—malignant glioma	0.000634	0.00313	CcSEcCtD
Celecoxib—ALB—brain—malignant glioma	0.000629	0.00588	CbGeAlD
Celecoxib—Back pain—Temozolomide—malignant glioma	0.000629	0.0031	CcSEcCtD
Celecoxib—Anaemia—Carmustine—malignant glioma	0.000622	0.00307	CcSEcCtD
Celecoxib—Vision blurred—Temozolomide—malignant glioma	0.000613	0.00302	CcSEcCtD
Celecoxib—ABCC4—brain—malignant glioma	0.000609	0.00569	CbGeAlD
Celecoxib—Leukopenia—Carmustine—malignant glioma	0.000603	0.00297	CcSEcCtD
Celecoxib—Anaemia—Temozolomide—malignant glioma	0.000601	0.00297	CcSEcCtD
Celecoxib—PTGS2—medulla oblongata—malignant glioma	0.000597	0.00557	CbGeAlD
Celecoxib—Angioedema—Temozolomide—malignant glioma	0.000594	0.00293	CcSEcCtD
Celecoxib—CA2—central nervous system—malignant glioma	0.000585	0.00546	CbGeAlD
Celecoxib—Vertigo—Temozolomide—malignant glioma	0.000585	0.00288	CcSEcCtD
Celecoxib—Leukopenia—Temozolomide—malignant glioma	0.000582	0.00287	CcSEcCtD
Celecoxib—Hypertension—Carmustine—malignant glioma	0.000581	0.00287	CcSEcCtD
Celecoxib—Palpitations—Temozolomide—malignant glioma	0.000575	0.00284	CcSEcCtD
Celecoxib—Myalgia—Carmustine—malignant glioma	0.000573	0.00283	CcSEcCtD
Celecoxib—Chest pain—Carmustine—malignant glioma	0.000573	0.00283	CcSEcCtD
Celecoxib—CA2—cerebellum—malignant glioma	0.000572	0.00534	CbGeAlD
Celecoxib—Anxiety—Carmustine—malignant glioma	0.000571	0.00282	CcSEcCtD
Celecoxib—Cough—Temozolomide—malignant glioma	0.000568	0.0028	CcSEcCtD
Celecoxib—Hypertension—Temozolomide—malignant glioma	0.000562	0.00277	CcSEcCtD
Celecoxib—CA4—brain—malignant glioma	0.00056	0.00523	CbGeAlD
Celecoxib—Confusional state—Carmustine—malignant glioma	0.000554	0.00273	CcSEcCtD
Celecoxib—Myalgia—Temozolomide—malignant glioma	0.000554	0.00273	CcSEcCtD
Celecoxib—Arthralgia—Temozolomide—malignant glioma	0.000554	0.00273	CcSEcCtD
Celecoxib—Anxiety—Temozolomide—malignant glioma	0.000552	0.00272	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00055	0.00271	CcSEcCtD
Celecoxib—Oedema—Carmustine—malignant glioma	0.000549	0.00271	CcSEcCtD
Celecoxib—Infection—Carmustine—malignant glioma	0.000546	0.00269	CcSEcCtD
Celecoxib—PTGS2—midbrain—malignant glioma	0.000546	0.0051	CbGeAlD
Celecoxib—Dry mouth—Temozolomide—malignant glioma	0.000542	0.00267	CcSEcCtD
Celecoxib—Thrombocytopenia—Carmustine—malignant glioma	0.000538	0.00265	CcSEcCtD
Celecoxib—Tachycardia—Carmustine—malignant glioma	0.000536	0.00265	CcSEcCtD
Celecoxib—Confusional state—Temozolomide—malignant glioma	0.000535	0.00264	CcSEcCtD
Celecoxib—PTGS2—spinal cord—malignant glioma	0.000532	0.00497	CbGeAlD
Celecoxib—Anaphylactic shock—Temozolomide—malignant glioma	0.000531	0.00262	CcSEcCtD
Celecoxib—Oedema—Temozolomide—malignant glioma	0.000531	0.00262	CcSEcCtD
Celecoxib—Infection—Temozolomide—malignant glioma	0.000528	0.0026	CcSEcCtD
Celecoxib—Anorexia—Carmustine—malignant glioma	0.000524	0.00258	CcSEcCtD
Celecoxib—Nervous system disorder—Temozolomide—malignant glioma	0.000521	0.00257	CcSEcCtD
Celecoxib—Thrombocytopenia—Temozolomide—malignant glioma	0.00052	0.00256	CcSEcCtD
Celecoxib—Skin disorder—Temozolomide—malignant glioma	0.000516	0.00254	CcSEcCtD
Celecoxib—Hyperhidrosis—Temozolomide—malignant glioma	0.000513	0.00253	CcSEcCtD
Celecoxib—Anorexia—Temozolomide—malignant glioma	0.000506	0.0025	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000501	0.00247	CcSEcCtD
Celecoxib—Insomnia—Carmustine—malignant glioma	0.000497	0.00245	CcSEcCtD
Celecoxib—Paraesthesia—Carmustine—malignant glioma	0.000493	0.00243	CcSEcCtD
Celecoxib—Dyspnoea—Carmustine—malignant glioma	0.00049	0.00242	CcSEcCtD
Celecoxib—Somnolence—Carmustine—malignant glioma	0.000488	0.00241	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000484	0.00239	CcSEcCtD
Celecoxib—Insomnia—Temozolomide—malignant glioma	0.00048	0.00237	CcSEcCtD
Celecoxib—Decreased appetite—Carmustine—malignant glioma	0.000478	0.00236	CcSEcCtD
Celecoxib—Paraesthesia—Temozolomide—malignant glioma	0.000477	0.00235	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000474	0.00234	CcSEcCtD
Celecoxib—Dyspnoea—Temozolomide—malignant glioma	0.000473	0.00234	CcSEcCtD
Celecoxib—Somnolence—Temozolomide—malignant glioma	0.000472	0.00233	CcSEcCtD
Celecoxib—Constipation—Carmustine—malignant glioma	0.00047	0.00232	CcSEcCtD
Celecoxib—Dyspepsia—Temozolomide—malignant glioma	0.000467	0.00231	CcSEcCtD
Celecoxib—CA2—brain—malignant glioma	0.000464	0.00434	CbGeAlD
Celecoxib—Decreased appetite—Temozolomide—malignant glioma	0.000462	0.00228	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000458	0.00226	CcSEcCtD
Celecoxib—Fatigue—Temozolomide—malignant glioma	0.000458	0.00226	CcSEcCtD
Celecoxib—Constipation—Temozolomide—malignant glioma	0.000454	0.00224	CcSEcCtD
Celecoxib—Feeling abnormal—Carmustine—malignant glioma	0.000453	0.00223	CcSEcCtD
Celecoxib—Gastrointestinal pain—Carmustine—malignant glioma	0.000449	0.00222	CcSEcCtD
Celecoxib—Feeling abnormal—Temozolomide—malignant glioma	0.000438	0.00216	CcSEcCtD
Celecoxib—Abdominal pain—Carmustine—malignant glioma	0.000434	0.00214	CcSEcCtD
Celecoxib—Body temperature increased—Carmustine—malignant glioma	0.000434	0.00214	CcSEcCtD
Celecoxib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000434	0.00214	CcSEcCtD
Celecoxib—PTGS2—central nervous system—malignant glioma	0.000432	0.00403	CbGeAlD
Celecoxib—PTGS2—cerebellum—malignant glioma	0.000422	0.00394	CbGeAlD
Celecoxib—Urticaria—Temozolomide—malignant glioma	0.000422	0.00208	CcSEcCtD
Celecoxib—Abdominal pain—Temozolomide—malignant glioma	0.00042	0.00207	CcSEcCtD
Celecoxib—Body temperature increased—Temozolomide—malignant glioma	0.00042	0.00207	CcSEcCtD
Celecoxib—Hypersensitivity—Carmustine—malignant glioma	0.000405	0.002	CcSEcCtD
Celecoxib—Asthenia—Carmustine—malignant glioma	0.000394	0.00194	CcSEcCtD
Celecoxib—Hypersensitivity—Temozolomide—malignant glioma	0.000391	0.00193	CcSEcCtD
Celecoxib—Asthenia—Temozolomide—malignant glioma	0.000381	0.00188	CcSEcCtD
Celecoxib—CYP3A4—central nervous system—malignant glioma	0.000377	0.00352	CbGeAlD
Celecoxib—Diarrhoea—Carmustine—malignant glioma	0.000376	0.00185	CcSEcCtD
Celecoxib—Pruritus—Temozolomide—malignant glioma	0.000376	0.00185	CcSEcCtD
Celecoxib—CYP2D6—central nervous system—malignant glioma	0.000371	0.00347	CbGeAlD
Celecoxib—Dizziness—Carmustine—malignant glioma	0.000363	0.00179	CcSEcCtD
Celecoxib—Diarrhoea—Temozolomide—malignant glioma	0.000363	0.00179	CcSEcCtD
Celecoxib—CYP2D6—cerebellum—malignant glioma	0.000363	0.00339	CbGeAlD
Celecoxib—Dizziness—Temozolomide—malignant glioma	0.000351	0.00173	CcSEcCtD
Celecoxib—Vomiting—Carmustine—malignant glioma	0.000349	0.00172	CcSEcCtD
Celecoxib—Rash—Carmustine—malignant glioma	0.000346	0.00171	CcSEcCtD
Celecoxib—Dermatitis—Carmustine—malignant glioma	0.000346	0.00171	CcSEcCtD
Celecoxib—Headache—Carmustine—malignant glioma	0.000344	0.0017	CcSEcCtD
Celecoxib—PTGS2—brain—malignant glioma	0.000343	0.0032	CbGeAlD
Celecoxib—Vomiting—Temozolomide—malignant glioma	0.000338	0.00167	CcSEcCtD
Celecoxib—Rash—Temozolomide—malignant glioma	0.000335	0.00165	CcSEcCtD
Celecoxib—Dermatitis—Temozolomide—malignant glioma	0.000334	0.00165	CcSEcCtD
Celecoxib—Headache—Temozolomide—malignant glioma	0.000333	0.00164	CcSEcCtD
Celecoxib—Nausea—Carmustine—malignant glioma	0.000326	0.00161	CcSEcCtD
Celecoxib—Nausea—Temozolomide—malignant glioma	0.000315	0.00156	CcSEcCtD
Celecoxib—CYP2D6—brain—malignant glioma	0.000295	0.00275	CbGeAlD
Celecoxib—CYP3A4—Metabolism—ASMT—malignant glioma	1.4e-05	4.19e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—IDH1—malignant glioma	1.39e-05	4.18e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—BCHE—malignant glioma	1.39e-05	4.18e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KRAS—malignant glioma	1.38e-05	4.15e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—IDH1—malignant glioma	1.38e-05	4.14e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT2—malignant glioma	1.38e-05	4.14e-05	CbGpPWpGaD
Celecoxib—CA14—Metabolism—AKT1—malignant glioma	1.38e-05	4.13e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—PIK3CA—malignant glioma	1.38e-05	4.13e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—SLC5A5—malignant glioma	1.38e-05	4.13e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.37e-05	4.12e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—PIK3CA—malignant glioma	1.37e-05	4.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTK2—malignant glioma	1.36e-05	4.09e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—PIK3CA—malignant glioma	1.36e-05	4.09e-05	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—AKT1—malignant glioma	1.35e-05	4.06e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SPHK1—malignant glioma	1.35e-05	4.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CD—malignant glioma	1.35e-05	4.04e-05	CbGpPWpGaD
Celecoxib—CA6—Metabolism—AKT1—malignant glioma	1.34e-05	4.03e-05	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—AKT1—malignant glioma	1.34e-05	4.03e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CASP3—malignant glioma	1.34e-05	4.03e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HES1—malignant glioma	1.34e-05	4.02e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL2—malignant glioma	1.34e-05	4.02e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KRAS—malignant glioma	1.34e-05	4.01e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SPHK1—malignant glioma	1.34e-05	4.01e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NCOR1—malignant glioma	1.33e-05	4e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CD—malignant glioma	1.33e-05	3.98e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.33e-05	3.98e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP2C18—malignant glioma	1.32e-05	3.96e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—malignant glioma	1.32e-05	3.96e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—BCAN—malignant glioma	1.31e-05	3.94e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP2C18—malignant glioma	1.31e-05	3.93e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.3e-05	3.9e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTEN—malignant glioma	1.3e-05	3.89e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTT1—malignant glioma	1.29e-05	3.88e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FGF2—malignant glioma	1.29e-05	3.86e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN2B—malignant glioma	1.28e-05	3.84e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PDGFRA—malignant glioma	1.28e-05	3.83e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—AKT1—malignant glioma	1.27e-05	3.82e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PIK3CA—malignant glioma	1.27e-05	3.81e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MMP9—malignant glioma	1.27e-05	3.8e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTEN—malignant glioma	1.26e-05	3.78e-05	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—AKT1—malignant glioma	1.25e-05	3.76e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SPP1—malignant glioma	1.24e-05	3.72e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.23e-05	3.7e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—AKT1—malignant glioma	1.23e-05	3.69e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PIK3CA—malignant glioma	1.23e-05	3.68e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—BCL2—malignant glioma	1.22e-05	3.67e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HES1—malignant glioma	1.22e-05	3.67e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NCOR1—malignant glioma	1.22e-05	3.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IFNG—malignant glioma	1.21e-05	3.64e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS1—malignant glioma	1.21e-05	3.63e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.21e-05	3.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MDM2—malignant glioma	1.2e-05	3.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—RAF1—malignant glioma	1.2e-05	3.6e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ERBB2—malignant glioma	1.19e-05	3.56e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—RAF1—malignant glioma	1.18e-05	3.55e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TERT—malignant glioma	1.17e-05	3.52e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CB—malignant glioma	1.17e-05	3.52e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PDGFRA—malignant glioma	1.16e-05	3.49e-05	CbGpPWpGaD
Celecoxib—CA12—Metabolism—AKT1—malignant glioma	1.16e-05	3.48e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CB—malignant glioma	1.16e-05	3.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PDGFB—malignant glioma	1.15e-05	3.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGFR1—malignant glioma	1.14e-05	3.42e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—VEGFA—malignant glioma	1.14e-05	3.42e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—AKT1—malignant glioma	1.14e-05	3.41e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PIK3CA—malignant glioma	1.13e-05	3.4e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—STAT3—malignant glioma	1.13e-05	3.38e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—BCHE—malignant glioma	1.13e-05	3.38e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.12e-05	3.37e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.12e-05	3.37e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—AKT1—malignant glioma	1.12e-05	3.37e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HIF1A—malignant glioma	1.12e-05	3.37e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—AKT1—malignant glioma	1.12e-05	3.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—AKT1—malignant glioma	1.11e-05	3.34e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—SLC5A5—malignant glioma	1.11e-05	3.34e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTP1—malignant glioma	1.11e-05	3.32e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PIK3CA—malignant glioma	1.09e-05	3.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CAV1—malignant glioma	1.09e-05	3.26e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.08e-05	3.25e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL1B—malignant glioma	1.08e-05	3.24e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CAT—malignant glioma	1.08e-05	3.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—malignant glioma	1.08e-05	3.23e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KDR—malignant glioma	1.07e-05	3.22e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HLA-A—malignant glioma	1.07e-05	3.21e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TERT—malignant glioma	1.07e-05	3.21e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTT1—malignant glioma	1.07e-05	3.2e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—malignant glioma	1.06e-05	3.18e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—IDH2—malignant glioma	1.06e-05	3.18e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTT1—malignant glioma	1.06e-05	3.17e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.05e-05	3.16e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—malignant glioma	1.05e-05	3.14e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PDGFB—malignant glioma	1.05e-05	3.14e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.04e-05	3.13e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGFR1—malignant glioma	1.04e-05	3.12e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—AKT1—malignant glioma	1.04e-05	3.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—F2—malignant glioma	1.03e-05	3.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FN1—malignant glioma	1.03e-05	3.1e-05	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	1.02e-05	3.07e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EGFR—malignant glioma	1.02e-05	3.07e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HIF1A—malignant glioma	1.02e-05	3.07e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BAD—malignant glioma	1.02e-05	3.06e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—NCOR1—malignant glioma	1.02e-05	3.05e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTEN—malignant glioma	1.01e-05	3.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NOTCH1—malignant glioma	1.01e-05	3.03e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—AKT1—malignant glioma	1e-05	3.01e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS1—malignant glioma	1e-05	3e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP2B6—malignant glioma	9.95e-06	2.99e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS1—malignant glioma	9.92e-06	2.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CD80—malignant glioma	9.91e-06	2.97e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CAV1—malignant glioma	9.91e-06	2.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APC—malignant glioma	9.89e-06	2.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CG—malignant glioma	9.89e-06	2.97e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	9.88e-06	2.96e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGF—malignant glioma	9.78e-06	2.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTPN11—malignant glioma	9.72e-06	2.92e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—malignant glioma	9.68e-06	2.9e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BAD—malignant glioma	9.32e-06	2.8e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—BCHE—malignant glioma	9.3e-06	2.79e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—BRAF—malignant glioma	9.3e-06	2.79e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—AKT1—malignant glioma	9.26e-06	2.78e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NOTCH1—malignant glioma	9.23e-06	2.77e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—BCHE—malignant glioma	9.22e-06	2.77e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SLC5A5—malignant glioma	9.19e-06	2.76e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PIK3CA—malignant glioma	9.16e-06	2.75e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SLC5A5—malignant glioma	9.11e-06	2.73e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—IDH1—malignant glioma	9.1e-06	2.73e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	9.09e-06	2.73e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—STAT3—malignant glioma	9.06e-06	2.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT2—malignant glioma	9.05e-06	2.72e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD80—malignant glioma	9.04e-06	2.71e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APC—malignant glioma	9.02e-06	2.71e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—VEGFA—malignant glioma	9.02e-06	2.71e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTP1—malignant glioma	8.96e-06	2.69e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGF—malignant glioma	8.92e-06	2.68e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PIK3CA—malignant glioma	8.89e-06	2.67e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—AKT1—malignant glioma	8.88e-06	2.66e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTPN11—malignant glioma	8.87e-06	2.66e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SPHK1—malignant glioma	8.81e-06	2.64e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CAT—malignant glioma	8.72e-06	2.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CD—malignant glioma	8.7e-06	2.61e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP2C18—malignant glioma	8.63e-06	2.59e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	8.61e-06	2.58e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—malignant glioma	8.6e-06	2.58e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.53e-06	2.56e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—BRAF—malignant glioma	8.48e-06	2.54e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—malignant glioma	8.37e-06	2.51e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGF2—malignant glioma	8.33e-06	2.5e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CAV1—malignant glioma	8.3e-06	2.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT2—malignant glioma	8.26e-06	2.48e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—NCOR1—malignant glioma	8.23e-06	2.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EGFR—malignant glioma	8.23e-06	2.47e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CD—malignant glioma	7.93e-06	2.38e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.93e-06	2.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MDM2—malignant glioma	7.79e-06	2.34e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—malignant glioma	7.78e-06	2.33e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RAF1—malignant glioma	7.76e-06	2.33e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ERBB2—malignant glioma	7.68e-06	2.3e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—malignant glioma	7.67e-06	2.3e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGF2—malignant glioma	7.6e-06	2.28e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CB—malignant glioma	7.58e-06	2.27e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CG—malignant glioma	7.56e-06	2.27e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—AKT1—malignant glioma	7.48e-06	2.24e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.44e-06	2.23e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTP1—malignant glioma	7.4e-06	2.22e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTP1—malignant glioma	7.33e-06	2.2e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARG—malignant glioma	7.29e-06	2.19e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL8—malignant glioma	7.28e-06	2.19e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—AKT1—malignant glioma	7.26e-06	2.18e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CAT—malignant glioma	7.2e-06	2.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PIK3CA—malignant glioma	7.15e-06	2.14e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CAT—malignant glioma	7.14e-06	2.14e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MDM2—malignant glioma	7.11e-06	2.13e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—RAF1—malignant glioma	7.08e-06	2.12e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PIK3CA—malignant glioma	7.04e-06	2.11e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERBB2—malignant glioma	7.01e-06	2.1e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTT1—malignant glioma	6.98e-06	2.09e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CASP3—malignant glioma	6.97e-06	2.09e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—malignant glioma	6.96e-06	2.09e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CB—malignant glioma	6.92e-06	2.07e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—malignant glioma	6.82e-06	2.04e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NCOR1—malignant glioma	6.8e-06	2.04e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NCOR1—malignant glioma	6.74e-06	2.02e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CAV1—malignant glioma	6.71e-06	2.01e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CD—malignant glioma	6.64e-06	1.99e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP9—malignant glioma	6.59e-06	1.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTEN—malignant glioma	6.55e-06	1.97e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS1—malignant glioma	6.54e-06	1.96e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.41e-06	1.92e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CG—malignant glioma	6.11e-06	1.83e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—BCHE—malignant glioma	6.08e-06	1.82e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC5A5—malignant glioma	6.01e-06	1.8e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTEN—malignant glioma	5.98e-06	1.79e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—VEGFA—malignant glioma	5.92e-06	1.77e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARG—malignant glioma	5.9e-06	1.77e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STAT3—malignant glioma	5.86e-06	1.76e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—AKT1—malignant glioma	5.84e-06	1.75e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—AKT1—malignant glioma	5.81e-06	1.74e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CB—malignant glioma	5.79e-06	1.74e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—AKT1—malignant glioma	5.75e-06	1.73e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CAV1—malignant glioma	5.54e-06	1.66e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CAV1—malignant glioma	5.49e-06	1.65e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—malignant glioma	5.44e-06	1.63e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CD—malignant glioma	5.38e-06	1.61e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—STAT3—malignant glioma	5.34e-06	1.6e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGFR—malignant glioma	5.32e-06	1.6e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.25e-06	1.57e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CG—malignant glioma	5.05e-06	1.51e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—malignant glioma	5.03e-06	1.51e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CG—malignant glioma	5.01e-06	1.5e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTEN—malignant glioma	5e-06	1.5e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—malignant glioma	4.97e-06	1.49e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARG—malignant glioma	4.87e-06	1.46e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGFR—malignant glioma	4.86e-06	1.46e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTP1—malignant glioma	4.84e-06	1.45e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARG—malignant glioma	4.83e-06	1.45e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CAT—malignant glioma	4.71e-06	1.41e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CB—malignant glioma	4.69e-06	1.41e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—malignant glioma	4.64e-06	1.39e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PIK3CA—malignant glioma	4.62e-06	1.39e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—malignant glioma	4.59e-06	1.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—malignant glioma	4.47e-06	1.34e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NCOR1—malignant glioma	4.45e-06	1.33e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CD—malignant glioma	4.44e-06	1.33e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CD—malignant glioma	4.4e-06	1.32e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PIK3CA—malignant glioma	4.22e-06	1.26e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTEN—malignant glioma	4.05e-06	1.21e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CB—malignant glioma	3.87e-06	1.16e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CB—malignant glioma	3.84e-06	1.15e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—malignant glioma	3.83e-06	1.15e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—malignant glioma	3.8e-06	1.14e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—AKT1—malignant glioma	3.77e-06	1.13e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CAV1—malignant glioma	3.62e-06	1.09e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PIK3CA—malignant glioma	3.53e-06	1.06e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—AKT1—malignant glioma	3.44e-06	1.03e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTEN—malignant glioma	3.34e-06	1e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTEN—malignant glioma	3.31e-06	9.94e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CG—malignant glioma	3.3e-06	9.9e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARG—malignant glioma	3.19e-06	9.56e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.9e-06	8.71e-06	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—AKT1—malignant glioma	2.88e-06	8.65e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PIK3CA—malignant glioma	2.86e-06	8.57e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.53e-06	7.59e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—malignant glioma	2.51e-06	7.52e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.36e-06	7.08e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PIK3CA—malignant glioma	2.34e-06	7.01e-06	CbGpPWpGaD
Celecoxib—ALB—Metabolism—AKT1—malignant glioma	2.33e-06	7e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTEN—malignant glioma	2.19e-06	6.56e-06	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—AKT1—malignant glioma	1.93e-06	5.78e-06	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—AKT1—malignant glioma	1.91e-06	5.73e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.54e-06	4.63e-06	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—AKT1—malignant glioma	1.26e-06	3.78e-06	CbGpPWpGaD
